Press Releases

Biothera Pharmaceuticals Presents Data Broadening Imprime PGG Mechanism of Action

Reduces expression of IDO, a potent suppressor of an anti-cancer T cell response Supplementation with IVIG boosts biomarker levels, restoring Imprime-driven pharmacodynamic responses EAGAN, MN — November 13, 2017 — Biothera Pharmaceuticals, Inc. announced today the presentation of clinical and preclinical research supporting the mechanism of action for the Company’s cancer immunotherapy Imprime PGG, which is currently being evaluated in combination with immune checkpoint inhibitor...

Read More


Biothera Pharmaceuticals Presents Preclinical Data Showing Imprime PGG Activates Natural Killer Cell-Mediated Tumor Killing

Data Presented at AACR-NCI-EORTC International Conference EAGAN, MN — October 30, 2017 — Biothera Pharmaceuticals, Inc. announced today the presentation of new preclinical findings showing that the Company’s Phase 2 cancer immunotherapy Imprime PGG activates Natural Killer (NK) cell-mediated killing of cancer cells. The data were presented at the ongoing AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, taking...

Read More


Biothera Pharmaceuticals Announces Presentations on Imprime PGG at Three Upcoming Healthcare Conferences

EAGAN, MN — September 28, 2017 — Biothera Pharmaceuticals, Inc. today announced that it will present new research at three upcoming healthcare conferences for Imprime PGG, Biothera’s novel phase 2 cancer immunotherapy.  These presentations will provide data strengthening the scientific foundation for the use of Imprime PGG in combination with immune checkpoint inhibitors.  The high profile late-breaking session of the AACR-NCI- EORTC will feature initial...

Read More


Biothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA in Non-Small Cell Lung Cancer

Big Ten Cancer Research Consortium conducting trial with funding from Merck EAGAN, MN — July 19, 2017 — Biothera Pharmaceuticals, Inc. today announced that the Big Ten Cancer Research Consortium has begun patient dosing in a Phase 1b/2 clinical study to evaluate Biothera’s Imprime PGG in combination with the Merck anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in second-line non-small cell lung cancer (NSCLC).  The University of Illinois...

Read More


Biothera Pharmaceuticals Announces Presentation at the Upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

EAGAN, MN — May 31, 2017 — Biothera Pharmaceuticals, Inc. announced today that a poster about the design of IMPRIME-1, the company’s ongoing Phase 2 clinical trial in advanced melanoma/triple negative breast cancer, will be presented at the 2017 ASCO Annual Meeting, taking place in Chicago, IL, June 2-6, 2017. The ASCO presentation details are as follows: Session Date & Time: Monday, June 5, 2017,...

Read More


Biothera Announces Three Presentations at Upcoming American Association for Cancer Research Annual Meeting

EAGAN, MN — March 27, 2017 — Biothera Pharmaceuticals Inc. announced today that it will present three scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 1-5 in Washington, D.C. One poster was selected for the late-breaking session that highlights the newest and most exciting research. Poster Presentations: Session Date & Time:  Monday, April 3, 8:00 AM – 12:00 PM Eastern...

Read More


Biothera Pharmaceuticals’ Phase 2 Study of Imprime PGG Combination Therapy in Non-Small Cell Lung Cancer Patients Published in Investigational New Drugs

EAGAN, MN — March 24, 2017 — Biothera Pharmaceuticals, Inc. today announced peer-reviewed publication of results of a randomized Phase 2 clinical study of the Company’s cancer immunotherapy Imprime PGG in combination with Erbitux® (cetuximab) and chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients. The study findings have been published online in the journal Investigational New Drugs. Completed by Biothera in 2013, the study was...

Read More


Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)

Study to combine therapies in patients with either advanced melanoma or metastatic triple negative breast cancer (TNBC) EAGAN, MN — February 23, 2017 — Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera’s Imprime PGG in combination with the Merck (known as MSD outside the United States and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with...

Read More


Biothera Pharmaceuticals to Discuss Imprime PGG Combination Therapy with Checkpoint Inhibitors at Molecular Medicine Tri-Conference 2017

EAGAN, MN — February 15, 2017 — Biothera Pharmaceuticals, Inc. today announced that it will deliver two presentations on its Phase 2 candidate Imprime PGG at the 24th annual Molecular Medicine Tri-Conference, taking place at the Moscone North Convention Center, San Francisco, February 19-24, 2017. Jeremy R. Graff, Ph.D., Chief Scientific Officer and Senior Vice President, Research at Biothera Pharmaceuticals, will present data showing that...

Read More


Biothera Pharmaceuticals and Merck Further Expand Research Collaboration to Include Phase 2 Clinical Trial in Head and Neck Cancer

Trial to Test Combination of Biothera’s Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab) EAGAN, MN — December 5, 2016 — Biothera Pharmaceuticals, Inc. today announced an expansion of its research collaboration with Merck (known as MSD outside the United States and Canada) to include a Phase 2 clinical study investigating Biothera’s Imprime PGG in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in second- and third-line patients...

Read More



Page 2 of 712345...Last »